Related Experiment Video
Updated: Jun 27, 2026
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Synthesis, Molecular Modeling and Assessment of Anticancer Activity of New Potential CYP17A1 Inhibitors
Michał K Jastrzębski1,2, Agnieszka Korga-Plewko3, Magdalena Iwan4
1Doctoral School, Medical University of Lublin, 20-093 Lublin, Poland.
Abstract:
Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge due to the ability of tumor cells to undergo intratumoral androgen synthesis, a process catalyzed by the CYP17A1 enzyme. The only CYP17A1 inhibitor available in therapy, abiraterone acetate, faces significant limitations due to its steroidal structure, which causes off-target effects and generates agonistic metabolites that paradoxically stimulate the androgen receptor (AR). This study presents the development of the D2AAK1M series, a novel class of non-steroidal potential CYP17A1 inhibitors based on a pyridine-piperidine scaffold. Through biomimetic design and molecular docking, we demonstrated that these compounds have the potential to coordinate the heme iron while achieving high shape complementarity within the catalytic pocket. In silico ADME profiling indicated superior physicochemical properties compared to abiraterone, including optimal lipophilicity, enhanced water solubility, and the potential to penetrate the blood-brain barrier for targeting CNS metastases. In vitro assay results correlated with a suggested mechanism, showing preferential cytotoxicity toward androgen-dependent LNCaP cells (AR+) while sparing AR-negative lines (DU145, PC3) and healthy human fibroblasts (BJ). Our compounds present a promising starting point for further development of non-steroidal CYP17A1 inhibitors.
Insights
Researchers developed novel non-steroidal CYP17A1 inhibitors to combat castration-resistant prostate cancer (CRPC). These compounds show promise in targeting tumor cells while offering improved properties over existing therapies.
Area of Science:
- Medicinal Chemistry
- Oncology
- Biochemistry
Background:
- Castration-resistant prostate cancer (CRPC) is a clinical challenge driven by intratumoral androgen synthesis via CYP17A1.
- Current therapy abiraterone acetate has limitations due to its steroidal structure, causing off-target effects and paradoxical androgen receptor (AR) stimulation.
Purpose of the Study:
- To develop a novel class of non-steroidal CYP17A1 inhibitors.
- To address the limitations of existing steroidal inhibitors like abiraterone acetate.
Main Methods:
- Design of a pyridine-piperidine scaffold for non-steroidal CYP17A1 inhibitors (D2AAK1M series).
- Biomimetic design and molecular docking to assess binding to the CYP17A1 catalytic pocket.
- In silico ADME profiling for physicochemical properties and blood-brain barrier penetration.
- In vitro cytotoxicity assays on androgen-dependent and -independent prostate cancer cell lines.
Main Results:
- The D2AAK1M series compounds demonstrated potential for heme iron coordination and high shape complementarity within the CYP17A1 catalytic pocket.
- In silico ADME profiling suggested superior physicochemical properties (lipophilicity, solubility, BBB penetration) compared to abiraterone.
- In vitro assays showed preferential cytotoxicity towards AR-positive LNCaP cells, sparing AR-negative cell lines and fibroblasts.
Conclusions:
- The novel D2AAK1M series represents a promising starting point for developing effective non-steroidal CYP17A1 inhibitors.
- These compounds offer potential advantages over abiraterone acetate for CRPC treatment, including improved safety and targeting of CNS metastases.
